Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$846.12M, compared with -$420.96M a year earlier.
Context
- Retained earnings amounted to 113.2% of total assets at the end of Q1 FY2026, down 13.0 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -101.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (765.13M) USD
- Year-over-year change
- -97.5%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (765.13M) | -97.5% |
| FY2024 | 2024-12-31 | (387.39M) | -68.1% |
| FY2023 | 2023-12-31 | (230.4M) | -19.2% |
| FY2022 | 2022-12-31 | (193.28M) | — |
Retained Earnings vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 retained earnings of -$846.12M is the 5th highest of the 8 companies compared; the peer median is -$374.81M.
- Its year-over-year change of -101.0% is the lowest of 7, against a peer median of -16.6%.
- Retained earnings amounts to 113.2% of total assets for ZBIO, versus a peer median of 333.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
| Dec 2025 | -$44.41M | +69.3% | — | 386.4% | |
| Mar 2026 | -$212.6M | +13.5% | — | 333.9% | |
UPBUpstream Bio, Inc. | Mar 2026 | -$374.81M | -71.9% | — | 117.8% |
| Mar 2026 | -$846.12M | -101.0% | — | 113.2% | |
| Mar 2026 | -$961.53M | -25.7% | — | 365.8% | |
| Mar 2026 | -$987.61M | -7.6% | — | 497.0% | |
| Sep 2026 | -$2B | -34.2% | — | 262.2% | |
| Peer median (excluding ZBIO) | -$374.81M | -16.6% | — | 333.9% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.